Solid Biosciences, Inc. (SLDB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.25-1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SLDB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Use proceeds from private placement and existing cash to fund operating expenses and capital expenditures into first half of 2028.
Stated as a priority in 2 of last 2 quarters. The company secured a private placement in 2025-Q4 and reiterated in 2026-Q1 that proceeds plus existing cash will fund operations into first half of 2028. This matches management's stated funding horizon and shows delivering progress on capital allocation.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Company estimates net proceeds from private placement plus existing cash will fund operations into first half of 2028.”
“Company entered securities purchase agreement for private placement to fund operations.”
Continue development and evaluation of SGT-003 in Phase 1/2 INSPIRE DUCHENNE clinical trial for Duchenne muscular dystrophy.
Newly stated in 2026-Q1. The company announced positive interim clinical data for SGT-003 in the Phase 1/2 INSPIRE DUCHENNE trial. No further quarterly statements were found, so progress is limited to this announcement.
“Announced positive new interim data from Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003.”
Control operating losses and cash used in operations while progressing clinical and capital plans.
Although not explicitly stated as a priority in the transcripts, the financials show persistent operating losses and increasing cash burn from -$23.7M in 2024-Q3 to -$52.6M in 2026-Q2 in cash from operations, and operating income worsening from -$39.9M to -$57.4M over the same period. This indicates ongoing cost and cash management challenges with limited progress.
Over the trailing year it converted 0.89x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.